万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生1>>传染病学
您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生3>>公共\环境与职业卫生

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY《感染控制与医院流行病学》 (官网投稿)

简介
  • 期刊简称INFECT CONT HOSP EP
  • 参考译名《感染控制与医院流行病学》
  • 核心类别 高质量科技期刊(T2), SCIE(2024版), 外文期刊,
  • IF影响因子
  • 自引率9.90%
  • 主要研究方向医学-PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH 公共卫生、环境卫生与职业卫生;INFECTIOUS DISEASES 传染病学

主要研究方向:

等待设置主要研究方向
医学-PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH 公共卫生、环境卫生与职业卫生;INFECTIOUS DISEASES 传染病学

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY《感染控制与医院流行病学》(月刊). Infection Control & Hospital Epidemiology publishes scientifically authoritative, clinically&...[显示全部]
征稿信息

万维提示:

1、投稿方式:在线投稿。

2、期刊网址:

https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology

3、投稿网址:

https://www.editorialmanager.com/iche/default.aspx

4、官网邮箱:iche.managingeditor@shea-online.org

5、期刊刊期:月刊,一年出版12期

2021年8月5日星期四

                                 

 

投稿须知【官网信息】

 

Instructions for authors

GENERAL INFORMATION

Manuscripts submitted to Infection Control & Hospital Epidemiology (ICHE) should consist of original investigations that will contribute to the fields of healthcare epidemiology, infection prevention and antimicrobial stewardship with the ultimate goal of improving healthcare safety. ICHE welcomes submissions that address the transmission of pathogens or that involve the use of epidemiological principles and methods to evaluate or improve the delivery of care within healthcare institutions. Examples of appropriate material include studies of infection surveillance, the impact of preventive measures on infection or antimicrobial resistance rates; analyses of resource use and costs related to infections or other adverse events in patients; occupational health; or pertinent regulatory issues.

Authors are responsible for ensuring that manuscripts adhere to the formats noted in the Instructions for Authors. Articles should be submitted electronically at the journal's submission website, at http://iche.edmgr.com.

ARTICLE TYPES

Original Articles should include a title page, a structured abstract of no more than 250 words (see below), a text of no more than 3,000 words, no more than 7 tables and figures, and no more than 40 references.

Concise Communications should include a title page, a narrative abstract of no more than 50 words, a text of no more than 1,200 words, no more than 2 tables or figures, and no more than 10 references.

Research Briefs should include a title page, a text of no more than 900 words, no more than 1 table or figure, and no more than 10 references. This category of article is intended for the presentation of short, focused, and evidence-based experimental observations: substantial preliminary and novel results of importance to the journal readership but not substantial enough in content to warrant a longer presentation. Research Briefs undergo the same peer review as longer article types.

Letters to the Editor should not exceed 900 words and should include no more than 1 table or figure and no more than 10 references.

Invited Reviews, including guidelines and position papers: committees, task forces, and authors under the auspices of the Society for Healthcare Epidemiology of America, and all others considering the preparation of a review, should contact the Editorial Office during the very earliest phases of development. The Editor-in-Chief will verify that there are no similar or overlapping documents under development. Anticipated length, format, number of citations, and mechanisms for peer review and publication by ICHE and the involvement of any other organizations will be negotiated with the journal and publisher well in advance of submission.

Commentaries are by invitation only. Please contact the journal office if you are interested in writing a Commentary.

MANUSCRIPT PREPARATION

Authors are encouraged to follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals; this is the format used in PubMed/MEDLINE. They should strive for a concise article that is unencumbered by excessive detail. Authors who are not fluent in English should have their manuscript checked by a native speaker of English and/or an editing service that provides such assistance. Manuscripts that do not follow the required format or are poorly prepared may be rejected for that reason.

For guidance regarding the reporting of randomized (CONSORT), observational (STROBE), meta-analyses (PRISMA), and other clinical trials, please consult www.equator-network.org.

Double space the entire manuscript, including title page, abstract, body, references, tables, and figure legends. Use left justification only, so that the right margin is ragged. Number pages consecutively, beginning with the title page. Use a standard font (such as Times New Roman or Helvetica) and set the font size to 12 points (for tables as well as text). Each component of the article should begin on a separate page, as follows: title page, abstract, body text, acknowledgments, references, appendices, figure legends, and tables. All these components must be in a single file, except any figures, each of which should be a separate file (see Figures and Figure Legends, below).

For revised submissions please upload both a clean version of the revised manuscript and a version with changes marked, either with tracked changes or highlighted.

Title Page

The title page should include the following information: (1) the title of the manuscript; (2) the names of the author(s), including each author's highest academic degree or professional certification; (3) the departmental and institutional affiliation of each author, including city, state, and country; (4) the name, address, telephone number, fax number, and e-mail address of the author responsible for correspondence, and (if different) the name and address to be used for reprint requests; (5) if relevant, a statement about any previous presentation of the data or findings in a preliminary report or abstract; (6) an abbreviated title of not more than 45 characters (including spaces), to be used as a running head in print and for search results online; and (7) a word count for the body of the text (ie, excluding the abstract and the references). Acknowledgment of financial support and potential conflicts of interest must be included and should be placed in the Acknowledgments section (see below).

Abbreviations should conform to those given in the AMA Manual of Style. Symbols for units of measurement (mm, mL) should not be followed by periods. Chemical or generic names of drugs, materials, and equipment are strongly preferred; a proprietary name may be given only after it is preceded by the generic or chemical name the first time it appears and must be followed by the name of the manufacturer or supplier. Terms and abbreviations must be defined at first use, separately for the abstract, the body, and each table and figure. Use only common abbreviations and use as few as possible; and do not abbreviate terms used fewer than 5 times. Abbreviate genus names after first mention.

Abstract

Original Articles should include a structured abstract of no more than 250 words. The following headings are suggested: Objective, Design, Setting, Patients (or Participants), Methods (or Interventions), Results, and Conclusions. If this list of headings is inappropriate, variations are permitted: for example, a study that involved no intervention would use the heading "Methods" rather than "Intervention"; or an analysis of an existing data set might use the heading "Methods" in place of both "Intervention" and "Setting." For brevity, parts of the abstract can be written in phrases rather than complete sentences, .e.g.,"Design: Retrospective cohort study". The contents of each section should conform to the guidelines below.

Objective. Begin with a clear statement of the precise objective or question addressed in the report. If more than one objective is addressed, indicate the main objective and state only key secondary objectives. If an a priori hypothesis was tested, it should be stated.

Design. Describe the basic design of the study. Include the duration of follow-up, if any. Use as many of the following terms as apply.

For intervention studies: randomized controlled trial; nonrandomized controlled trial; double-blind; placebo controlled; crossover trial; before-after trial.

For studies of screening and diagnostic tests: indicate the criterion standard against which a new or alternative test is being compared; blinded or masked comparison.

For studies of prognosis: inception cohort (subjects assembled at a similar and early time in the course of the disorder and followed thereafter); cohort (subjects followed forward in time, but not necessarily from a common starting point); validation cohort or validation sample, if the study involves the modeling of clinical predictions.

For studies of causation: randomized controlled trial; cohort; case-control; survey (preferred to "cross-sectional study").

For descriptions of the clinical features of medical disorders: survey; case series.

For studies that include a formal economic evaluation: cost-effectiveness analysis; cost-utility analysis; cost-benefit analysis. For new analyses of existing data sets, the data set should be named and the basic study design disclosed.

Setting. To assist readers in determining the applicability of the report to their own clinical circumstances, include a brief description of the study setting(s) such as: primary or tertiary referral center, private or public institution, or an ambulatory or acute care setting.

Patients or participants. Provide information on important eligibility criteria, and key sociodemographic features of patients and how they were selected, including the number of otherwise eligible subjects who were approached but refused to participate. If matching was used for comparison groups, specify the characteristics that were matched. In follow-up studies, the proportion of participants who completed the study must be indicated. In intervention studies, the number of patients withdrawn because of adverse effects should be given.

For selection procedures, these terms should be used, if appropriate: random sample ("random" refers to a formal, randomized selection in which all eligible subjects have a fixed and usually equal chance of selection); population-based sample; referred sample; consecutive sample; volunteer sample; convenience sample.

Intervention(s). Describe the essential features of any interventions, including the method and duration of administration. The intervention should be named by its most common clinical name (eg, the generic term "oseltamivir"), the brand name of a drug, if a specific product was studied, and the name of the manufacturer or supplier for any product(s) mentioned in the manuscript, including software.

Results. Give the main results of the study in narrative form. Define measurements that require explanation for the expected audience of the manuscript. If possible, the results should be accompanied by objective data and the exact level of statistical significance. For comparative studies, confidence intervals should relate to the differences between groups. When risk changes or effect sizes are given, indicate absolute values, so that the reader can determine the absolute, as well as relative, impact of the finding. Approaches such as "number needed to treat" to achieve a unit of benefit are encouraged when appropriate. Studies of screening and diagnostic tests should use the terms sensitivity, specificity, and likelihood ratio. If predictive values or accuracy are given, prevalence or pretest likelihood should be given as well.

Conclusions. Only those conclusions of the study that are directly supported by the evidence reported should be given, along with the clinical application; indicate whether additional study is required before the information should be used in normal clinical settings. Equal emphasis must be given to positive and negative findings of equal scientific merit.

Clinical trials identifier. If your manuscript is the report of a randomized clinical trial that has been registered in a public trials registry, please provide the trial registry name, the registration identification number, and the URL for the registry at the end of the abstract. This information will be published in the journal if the manuscript is accepted.

……

更多详情:

https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/information/instructions-contributors


  • 万维QQ投稿交流群    招募志愿者

    版权所有 Copyright@2009-2015豫ICP证合字09037080号

     纯自助论文投稿平台    E-mail:eshukan@163.com


投稿问答最小化  关闭